08:42 AM EDT, 08/01/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported Q2 adjusted earnings Thursday of $0.56 per diluted share, compared with an adjusted loss of $1.62 a year earlier.

Analysts polled by Capital IQ expected an adjusted loss of $0.69.

Revenue for the quarter ended June 30 was $659.8 million, compared with $318.8 million a year earlier.

Analysts surveyed by Capital IQ expected $444.2 million.

The company raised its full-year 2024 product revenue guidance to now be in the range of $1.58 billion to $1.65 billion from the prior guidance range of $1.4 billion to $1.50 billion.

Shares of the company rose more than 8% in recent premarket activity.

Price: 258.00, Change: +20.54, Percent Change: +8.65